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The treatment of invasive candidiasis has changed greatly in the past decade and must continue to evolve if we
are to improve outcomes in this serious infection. A review of recent history may provide insights for the future.
The morbidity and mortality of invasive candidiasis remain difficult to measure despite an obvious clinical bur-
den. Current treatment guidelines now recommend echinocandins as first-line empirical treatment, with fluco-
nazole as an acceptable alternative for selected patients, reflecting the efficacy demonstrated by echinocandins
and increasing resistance observed with fluconazole. The selection of antifungal therapy now must consider not
only resistance but also the shift in predominance from Candida albicans to non-albicans species, notably
Candida glabrata. The recent emergence of Candida auris has been met with great interest, although the longer-
term implications of this phenomenon remain unclear. The broad goal of treatment continues to be administra-
tion of safe, efficacious antifungal therapy as soon as possible. Diagnostic methods beyond traditional blood
culture present an opportunity to shorten the time to an accurate diagnosis, and earlier treatment initiation
based on prophylactic and empirical or pre-emptive strategies seeks to ensure timely therapeutic intervention.
In addition, there are novel agents in the antifungal pipeline. These developments, as well as ongoing studies of
dosing, toxicity and resistance development, are important items on the current research agenda and may play
a role in future changes to the treatment of invasive candidiasis.
Introduction
The challenge of invasive candidiasis extends well beyond the past
10 years,1 as does the history of its treatment.2,3 However, our
most recent experience in the management of this serious fungal
infection provides a useful context for understanding current
standards of treatment and areas of research focus in the future.
This review discusses key changes and trends that have had
an impact on where we are today, as well as ongoing develop-
ments that may influence the future of treatment for invasive
candidiasis.
Morbidity and mortality, then and now
Morbidity
Denominator choice is essential for understanding and interpret-
ing results from epidemiological studies of candidaemia and inva-
sive candidiasis. Frequently used denominators are the total
number of admissions, or (in specific subpopulations of in-hospital
patients) the number of admissions per observed ward or clinical
entity, or the attack rate per number of patient days at risk. The dif-
ficulty with diagnosing invasive candidiasis, e.g. the inability to
obtain a biopsy in many patients, leads to categories of lower diag-
nostic certainty. Unproven cases add to the inaccuracy of estimat-
ing case numbers of invasive candidiasis.4 Delayed diagnosis
impacts current strategies,5 and successful clinical trials evaluating
treatment early in the course of disease are difficult to design.6,7
The incidence of invasive candidiasis in a population-based
study including ICU and non-ICU wards was 0.61 per 1000
admissions in Petah-Tikva, Israel, between 2007 and 2014.8
Focusing on ICU patients, higher rates are expected. Between
2006 and 2008, a European study conducted in 14 countries
found a median rate of 9 candidaemias per 1000 ICU admissions
(range 3–28) and regional incidence differences, with Finland
having the lowest rate and Italy and Spain having the highest.9
The candidaemia rate per 10000 ICU patient-days per year was
increasing (from 1.25 to 3.06) in an Italian tertiary care hospital
between 1999 and 2003.10 The US American TRANSNET study
reported an invasive candidiasis incidence rate of 3.8% among
solid organ transplant recipients.11
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Recently, the fungaemia rate in 145030 European in-hospital
cancer patients has been determined to be 0.23%. The highest
rate in that study occurred in HSCT recipients (1.55%), whereas
patients with solid tumours had a lower risk (0.15%).12
Mortality
Since echinocandins became recommended as first-line treat-
ment for candidaemia,13–16 attributable mortality rates would
have been expected to decline following widespread echinocandin
use. This, however, is difficult to prove and remains a pressing topic
in the current research agenda.17,18
Candidiasis is associated with high crude mortality rates, reach-
ing up to 60%, although attributable mortality is difficult to estab-
lish due to the presence of confounders such as a patient’s
underlying conditions and septic shock.7 Various studies have
attempted to calculate Candida-attributable mortality and have
reported highly variable rates (5%–70%). Patients in large, well-
designed, randomized clinical trials that enrolled between 1989
and 2006 had an average mortality rate of 31%.19–26 That mortal-
ity rate may reflect the lower end because of the general selection
bias of prospective trials. In 1988, Wey et al.27 reported crude and
attributable in-hospital mortality rates of candidaemia of 57% and
38% in a case–control study. A follow-up study from the same hos-
pital analysed 108 matched pairs between 1997 and 2001 and
found practically unchanged crude and attributable mortality
rates of 61% and 49%, respectively.28 An EORTC study on 249 can-
cer patients treated at 30 tertiary care cancer centres in
Europe and the Middle East between 1992 and 1994 demon-
strated a 39% overall mortality at 30 days.29 European cancer
patients treated between 2005 and 2009 had a virtually
unchanged 36% death rate at 4 weeks after diagnosis of candi-
daemia.12 In an ICU population (n"200) studied between 1992
and 2000, researchers from the Netherlands found a generally
high mortality rate (43%) in their patients, which did not
significantly differ from mortality in those with candidaemia
(48%).30 In an epidemiological candidaemia study conducted in
the Paris area from 2002 to 2014, the risk of death was particularly
higher in those admitted to the ICU and those with haematological
cancer or solid tumours. Crude death rates in ICU patients had sig-
nificantly increased over the 11 year observation period, i.e. from
18% to 58%.31 When comparing general medical and surgical
ward patients with those on an ICU within the same hospital, the
highest 30 day mortality rates were found in the ICU (75%), fol-
lowed by medical (63%) and surgical wards (39%).8
Overall, mortality is not decreasing. Rates depend on the clinical
setting and range from 40% to 60% at 30 days post diagnosis of
candidaemia.
Microbiological context
There is a vast body of literature on the epidemiology of candidia-
sis. One essential aspect is the relative frequency of individual spe-
cies. The relative distribution of Candida spp. is clinically important
since it drives initial antifungal choice when the microbiologist
reports yeast in a (blood) culture.32 That laboratory result is the
first step in establishing the diagnosis of invasive candidiasis and
its most common form, i.e. candidaemia.5 Since mortality in
untreated candidaemia increases by the hour,33 clinicians strive to
hit early and hit hard.14 For many years a drug of choice in that clin-
ical scenario was fluconazole.34
Candida spp. distribution varies with the patient population
characteristics as well as by region and hospital, and even between
individual wards.35 These factors render it difficult to document a
shift from fluconazole-susceptible species to less-susceptible spe-
cies.36 Usually, the proportion of C. albicans is addressed as part of
the whole. Species shifts within the individual patient are well
documented and depend on the duration of exposure to
antifungals.37,38
In the 1990s and early 2000s, the variable epidemiology of can-
didaemia was described by the following exemplary studies. In a
nationwide Swiss study conducted from 1991 to 2000, 1137
candidaemias were observed. Incidence rates were stable and
C. albicans accounted for 66% of the episodes, without changes
over time.39 A study from a German tertiary care hospital found a
stable species distribution from 1995 to 2004. While the overall
number of candidaemias almost doubled, C. albicans accounted
for 57.1% of 296 blood culture isolates, and no trend in favour of
non-albicans species was seen.40 The European Confederation of
Medical Mycology (ECMM) conducted a surveillance study enrolling
2089 candidaemia cases throughout Europe from 1997 to 1999.
C. albicans accounted for 56% of isolates.35 From 1999 to 2003,
182 episodes of candidaemia among patients in a northern Italian
ICU occurred. Analyses revealed an overall increase in the
incidence of candidaemia and a decrease in the proportion of
C. albicans to ,30%. Interestingly, the prophylactic and empirical
use of fluconazole inversely correlated with the species shift.10
A similar decline in the proportion of C. albicans was found in a
recent population-based study from Israel.8 A study from
Northern Ireland focused on 151 candidaemias diagnosed from
2001 to 2006 and found an increasing proportion of C. albicans
over time.41 A meta-analysis of such epidemiological studies
presents an unusual but potentially interesting approach. Recently
such a study was attempted, but the full publication is pending.
The analysis compared epidemiology before and after 2004 and
found a general decrease in C. albicans as a cause of candidaemia,
which was more pronounced in ICU settings, where it exceeded
10%. Still, the overall C. albicans proportion remained .50%.42
In line with these findings, a US study on solid organ transplant
recipients recently reported a rate of C. albicans of 46%.11
Developments that are more recent show the emergence of
Candida auris since 2012. Simultaneous reports from Asia, Africa
and South America posed the question of phylogenetic related-
ness. Whole-genome sequencing of 54 patient isolates, as well as
the isolate of the first reported case (an ear infection) from Japan,
demonstrated that clades differed between geographical regions
and that within a region isolates were clonal. C. auris is of particular
interest because of generally high rates of antifungal resistance,
including a 7% rate of echinocandin resistance.43,44 In the first
hospital outbreak of C. auris in the UK, which was reported in 2016
and had been ongoing since 2015, all isolates had high-level resist-
ance to fluconazole and exhibited variable amphotericin B sus-
ceptibility, but the majority were echinocandin susceptible.45
Recent cases of C. auris infection in continental Europe and
ongoing transmission in the USA have been reported and have
attracted great attention.46–48 However, at this point in time, it
remains enigmatic if and how C. auris will influence future man-
agement strategies for invasive candidiasis.49
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Diagnostic advances
Considering the importance of timely initiation of antifungal treat-
ment, non-culture-based diagnostics have shown promising per-
formance for the early detection of invasive candidiasis. Several
tests are available that can be separated in a chronological
approach into assays for the periods before and after microbiologi-
cal identification and susceptibility testing results (Table 1). Their
applicability to ICU patients remains debated in many instances.
Most reports focus on fungal identification, whereas the impact on
clinical outcome remains under-evaluated.
Before identification and susceptibility testing results
These tests are used as an early warning in patients suspected of
having invasive candidiasis and/or to help in the decision-making
process for initiating antifungal therapy. Their use for antifungal
stewardship remains minimally investigated. A major trend in
recent years is the emergence of combined approaches using dif-
ferent biomarkers or repeated measures of several markers.50–54
Candida PCR
No officially standardized PCR test is yet available and the useful-
ness of PCR as an early marker of invasive candidiasis is a subject of
debate.55,56 Many limitations have been pointed out, including
costs and the labour-intensive nature of its use. Reports in ICU
patients have demonstrated good sensitivity, specificity and pre-
dictive values.57,58 The comparison of the capacities of PCR testing
for detection of bacterial DNA compared with fungal DNA has
demonstrated a lower sensitivity for fungal infection.59 The value
of PCR compared with other techniques remains a subject of
debate. Some authors have reported better results with PCR, espe-
cially in deep-seated candidiasis,51,58 whereas others have
observed lower discriminating capacities.54 Overall, the value of
Table 1. Non-culture based diagnostics15,134
Method or
marker
Sensitivity/
specificity Potential advantages Potential limitations
Assays before identification and susceptibility results
Candida PCR 95%/92% (suspected); 85%/38%
(probable)
• shorter time to diagnosis
• species identification
• detection of resistance markers
• detection of deep-seated candidiasis
• cost, inconvenience
• lack of universally standardized meth-
ods (e.g. specimen type) or perform-
ance validation
Mannan-Ag and
anti-mannan
Ab
58%/93% (mannan-Ag); 59%/83%
(anti-mannan Ig); 83%/86%
(combined)
• best when used together and for
detecting C. albicans, C. glabrata or
C. tropicalis
• limited sensitivity/specificity when
used individually and for detecting
C. parapsilosis and C. guilliermondii
• uncertain reliability in immunocom-
promised hosts, uncertain utility for
deep-seated candidiasis
BDG 75%–80%/80% • pan-fungal marker for patients at risk
for other systemic infections (e.g. with
Aspergillus spp. or Pneumocystis jiro-
vecii, in HSCT recipients)
• detection of deep-seated candidiasis
• high negative predictive value
• can detect infection days or weeks in
advance of culture-based diagnosis
• prophylactic or empirical antifungal
treatment may impact test
performance
• lower sensitivity for C. parapsilosis
• false-positive results higher for
patients in ICU, with colonization,
other systemic infections, multiple
therapeutic interventions; may require
more than one consecutive positive
result
CAGTA 77%–89%/91%–100% • high negative predictive value (93.9%)
• unaffected by colonization or antifun-
gal use
• limited experience/data
T2MR 91.1%/99.4% per assay • shorter time to diagnosis
• high specificity
• low limit of detection
• limited experience/data
Assays after identification and susceptibility results
MALDI-TOF .90% • rapid results (within minutes)
• ability to identify genus, species, strain
and potential resistance patterns
• lack of experience/data
Bassetti et al.
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PCR compared with other techniques remains to be clearly
established.
Mannan antigen (mannan-Ag) and anti-mannan
antibodies (anti-mannan-Ab)
The value of these markers of the Candida cell wall has been
assessed in ICU and immunocompromised patients.54,60 The sen-
sitivity and specificity of mannan-Ag have been disappointing in
several studies.54,61 The combination of mannan-Ag and anti-
mannan-Ab assays significantly increases the sensitivity and spe-
cificity of the test.62 The best sensitivity results have been reported
with C. albicans and C. glabrata,62 whereas disappointing results
have been reported in C. parapsilosis and C. guilliermondii
infections.52 The use of mannan-Ag/anti-mannan-Ab assays has
not been rigorously assessed in patients with deep-seated candi-
diasis, such as intra-abdominal Candida infections.63
1,3-b-D-Glucan (BDG)
This pan-fungal marker for invasive fungal infections, except zygo-
mycetes and Cryptococcus neoformans, has been proposed as a
marker for the early detection of invasive candidiasis. Several
false-positive results have been reported for other fungal and bac-
terial infections and with many therapeutic interventions, includ-
ing antibiotics, haemodialysis, surgical gauze, blood products and
intravenous immunoglobulins.64–66 The conventional cut-off value
for the diagnosis of invasive candidiasis is 80 pg/mL, but several
thresholds have been discussed.54 The sensitivity of the test seems
to vary by Candida species, with the lowest sensitivity being
reported for C. parapsilosis. Therefore, test results for this species in
particular should be carefully evaluated.67 BDG positivity can
anticipate the diagnosis of invasive candidiasis by a median of
5–8 days before culture-based diagnosis.68,69 Repeated measure-
ments have been proposed to increase the diagnosis accuracy and
the best results have been obtained when two consecutive analy-
ses were positive.68,70 The high negative predictive value of the
test allows its use to exclude invasive candidiasis.70,71 The decline
in BDG concentrations in successfully treated patients suggests its
use as a surrogate for clinical response, but this approach is
debated,68,70,72 in particular because of persistent BDG levels of
.80 pg/mL for several weeks after initiation of therapy.68,73,74
A relationship between BDG and high-grade Candida spp. coloniza-
tion has been evidenced in several studies.54,68,74 Two consecutive
BDG samples of80 pg/mL were able to differentiate invasive can-
didiasis from high-grade colonization.69
Candida albicans germ tube antibodies (CAGTA)
The detection by indirect immunofluorescence assay of CAGTA is a
recent and promising approach. A positive CAGTA test corresponds
to a serum titre of 1/160.75 In the ICU setting, the test has been
assessed in patients having significant BDG concentrations
(259 pg/mL) associated with a positive CAGTA value (sensitivity
90.3%, negative predictive value 93.9%).50 The promise of the
combined approach has been confirmed using a lower BDG cut-off
(80 pg/mL) in three cohorts of patients with a large proportion of
ICU cases and severe abdominal cases.53,54,69 Significant CAGTA
titres were observed in patients with invasive candidiasis treated
with systemic antifungals for various types of Candida, including
C. albicans, C. parapsilosis and C. glabrata.69 In patients receiving
antifungals, no significant changes in the CAGTA kinetics were
observed.69 A positive CAGTA test in a patient with candidaemia
seems to be suggestive of deep-seated candidiasis.76 The high
sensitivity and negative predictive value of the combination
BDG/CAGTA could be a reliable tool for evaluating the discontinua-
tion of empirical antifungal therapy.53
T2 magnetic resonance
The nanodiagnostic method of T2 magnetic resonance (T2MR) is
another recent development of interest. T2MR utilizes whole-blood
samples to detect and identify Candida spp. and can produce
results on a scale of hours versus days with culture-based testing.
In a clinical trial of T2MR sensitivity and specificity, the mean time
to species identification was 4.4 h, with a 91.0% overall rate of sen-
sitivity per patient.77 There was high specificity overall and for
non-albicans species (99.9% for C. krusei/glabrata, 99.3% for
C. parapsilosis). The study also reported a low limit of detection
(1 cfu/mL) for C. krusei/C. tropicalis, which may be useful in cases
where fungal burden is low (e.g. gastrointestinal infection, patients
receiving antifungal therapy).
After identification and susceptibility testing results
MALDI-TOF
The promise of these tools is to expedite the selection of appropri-
ate therapy by providing prescribers with identification of the
organisms and their potential resistance patterns. Several techni-
ques are available and used routinely for identification of microor-
ganisms from isolated colonies, obtained by culture, in a few
minutes with an accuracy rate of.90%.78,79 Clinical evaluations of
these tests have shown decreased time to organism identification
and improved time to effective anti-infective therapy.80
In summary, the two approaches of early detection of patients
at risk using biomarkers and early identification of Candida using
rapid tests (PCR, T2MR, MALDI-TOF) complement one another.
Combinations of these tools in bundles and repeated assessments
could be hypothesized to speed up the management of these
high-risk cases in the near future. However, the added value of
these combined techniques remains to be evaluated.
Approaches to prophylactic, pre-emptive and
empirical treatment
Over the last decade, early antifungal agents have been prescribed
in non-neutropenic adult patients admitted to the ICU for various
purposes corresponding to prophylaxis or pre-emptive or empirical
therapies.
Prophylaxis strategy is usually defined as administration of anti-
fungal agents to patients with risk factors for invasive candidiasis
without clinical signs and symptoms of infection.81,82 The concept,
initiated almost 40 years ago, remains an important issue in rou-
tine practice, as illustrated in European observational studies
where prophylaxis was reported in 10%–16.6% of the patients or
units.83,84 Over the last decade, 10 articles have focused on the
prevention of fungal infection in ICU patients in randomized con-
trolled trials involving echinocandins, intravenous or oral flucona-
zole and oral nystatin.85 However, the quality of evidence is low in
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many studies, leading to uncertainty with regard to the reduction
of mortality, reduction of invasive candidiasis, or the risks of fungal
colonization or resistance development with wide-scale use.85
Despite the large number of publications, it is not yet possible to
identify among the critically ill patients those who deserve prophy-
laxis, or determine the agent to select, when to start it, at what
dose, how long to use it or what is the best monitoring regime for
this procedure. The current IDSA guidelines do not provide specific
recommendations, only suggesting use of fluconazole or echino-
candins in high-risk patients in adult ICUs with high rates (5%) of
invasive candidiasis, without clear definitions of the target popula-
tion or durations of prophylaxis.15 Nevertheless, research and clini-
cal experience have continued to explore strategies for antifungal
prophylaxis, not only in the ICU but also in haematology/oncology
and transplant infectious disease. Evidence regarding prophylaxis
in these settings is reviewed separately in this Supplement.86,87
Various definitions have been proposed for pre-emptive ther-
apy over the last 10 years.14,82,85 Consequently, the concept of
pre-emptive strategy has been an area of confusion as treated
patients have been described by some authors as having received
empirical therapy while others refer to pre-emptive or presumptive
therapy.81 In addition to the differing nomenclature, tools for
detecting the target population are not clearly defined, although
the use of biomarkers has been suggested to guide the
prescriptions.71,88,89 These poorly defined topics could explain the
downward trend in the number of recent publications, as illus-
trated by the absence of recommendation for pre-emptive ther-
apy in Canadian guidelines90 and in the 2016 updated IDSA
guidelines.15 The only two recently published randomized,
placebo-controlled trials evaluating pre-emptive therapy with
echinocandins in ICU patient populations were unable to provide
conclusive evidence that this policy was effective in preventing
invasive candidiasis.6,91 Both studies were conducted in patients at
higher risk of infection; cardiovascular and gastrointestinal surgery
were among the top reasons for ICU admission in one study,91 and
all patients required surgery for intraabdominal infection in the
other.6 Two other studies, one using the term ‘prophylaxis’92 and
the second ‘empiric’,7 could also be assimilated to pre-emptive
therapy but neither study demonstrated a benefit with early anti-
fungal therapy. Interestingly, pre-emptive therapy remains widely
used in ICU patients, accounting for between 18.2% and 28% of
antifungal therapy in European ICUs.83,84
Empirical therapy requires complex alignment between appro-
priateness (of dose and spectrum of activity) and timing. As noted
previously, early intervention is known to benefit mortality and is a
goal of treatment.14,33 However, more work is needed to specify
criteria for starting empirical antifungal therapy in non-
neutropenic critically ill patients. Empirical treatment is usually
considered in patients with risk factors for invasive candidiasis and
no other known cause of fever, based on the clinical assessment of
risk factors, serological markers for invasive candidiasis and/or cul-
ture data from non-sterile sites.82 Early initiation of antifungal
therapy is increasingly popular, corresponding to between 45%
and 65% of all the prescriptions in European ICUs,83,84,93 raising
questions of whether warnings about toxicity, cost and resistance
emergence83,94 are going unheeded. The lack of published
randomized controlled trials demonstrating the efficacy of empiri-
cal therapy, with any drug, limits broad recommendations on
appropriateness and timing. Amidst these research challenges,
the potential benefits for high-risk ICU patients with sepsis con-
tinue to be debated and explored.7,92,95,96 In a retrospective cohort
of patients with invasive candidiasis, early empirical treatment has
been reported to achieve better clinical stability.97 A better progno-
sis with empirical therapy has been reported in bloodstream infec-
tions but only in combination with catheter removal,98 and this
benefit has not been reported in Candida peritonitis.99
Treatment experience and guidelines
Recent updates to treatment guidelines reflect the changes and
trends being described. Key recommendations from the IDSA and
ESCMID are summarized in Table 2.14,15 As previously mentioned,
the benefit of empirical or pre-emptive therapy to Candida-related
mortality remains unclear, especially among critically ill patients
hospitalized in the ICU. Furthermore, challenges in the use of anti-
fungal prophylaxis include correct selection of the appropriate
high-risk populations, in order to avoid overtreatment that might
impact fungal ecology and select resistance.100 A double-blind pla-
cebo-controlled trial did not support the use of antifungal empiri-
cal therapy in high-risk, critically ill patients presenting with
ICU-acquired sepsis, Candida spp. colonization and multiple organ
failure. In this patient population, treatment with micafungin did
not increase fungal infection-free survival compared with pla-
cebo.91 Empirical therapy with micafungin in high-risk hosts, how-
ever, was associated with a decrease in the incidence of proven
disease.7
The 2016 updated guidelines from the IDSA recommend first-
line treatment for Candida spp. infection with an echinocandin
(e.g. caspofungin, anidulafungin or micafungin), rather than fluco-
nazole, based on the increasing prevalence of Candida spp. with
decreased susceptibility to fluconazole, especially in critically ill
patients.14,15,63,81,90
Evidence to support the use of an echinocandin as first-line
therapy in the treatment of candidiasis has been provided from
clinical trials and observational studies. A randomized trial com-
paring anidulafungin with fluconazole for the treatment of candi-
daemia and invasive candidiasis in non-neutropenic patients
showed a significantly higher efficacy with the use of anidulafun-
gin compared with fluconazole (76% versus 60%; P,0.01).13
Multivariate analyses also confirmed the superiority of anidulafun-
gin compared with fluconazole for infections due to fluconazole-
susceptible C. albicans and over a broad range of APACHE II
scores.13,101 Although two prospective studies found no correla-
tion between antifungal treatment type and prognosis,99,102 a
quantitative review of randomized trials gathering 1915 patients
from seven studies reported that treatment with an echinocandin
was a factor in decreased mortality and a factor in increased suc-
cess.19 In the ICU setting, emerging evidence supports the superi-
ority of this antifungal class.103,104 In this group, however, complex
pathophysiological changes may affect echinocandin concentra-
tion, and further studies to assess the clearance and correct
dosing of antifungals are warranted to avoid suboptimal
concentrations.105–107
A recent large, randomized trial comparing a new azole, isavu-
conazole, with caspofungin confirmed higher rates of success for
the group of patients treated with the echinocandin (71.1% versus
60.3%, respectively). This result was not limited to critically ill
patients and also applied to subjects with low APACHE II scores.16
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In a retrospective study, echinocandin use as well as prompt anti-
fungal therapy and adequate source control were associated
with increased survival in patients with septic shock due to
Candida spp.108
In a retrospective cohort study analysing patients infected with
C. glabrata, treatment failure was associated with ICU admission,
whereas echinocandin therapy was associated with complete clin-
ical response at day 14.109
In the trial comparing anidulafungin with fluconazole, a trend
towards lower mortality was demonstrated for patients treated
with anidulafungin, although the difference between the two
treatment arms was not significant (23% versus 31%, P"0.13).13
Treatment with fluconazole, however, did not show a significant
association with mortality, either as empirical or definitive therapy
or in patients with septic shock, compared with echinocandins in a
prospective multicentre study.110 Two cohort studies did not dem-
onstrate significantly increased survival rates with echinocandin
treatment compared with fluconazole treatment in C. glabrata
infections.109,111 Overall, the results appear conflicting and difficult
to compare since many trials were not powered for mortality
Table 2. Key IDSA/ESCMID recommendations by treatment strategy14,15
Strategy Case
Recommendation
Notesantifungal SoR/QoEa
Targeted confirmed infection iv echinocandin (caspofungin,
anidulafungin, micafungin)
strong/I;14
strong/high15
For 14 days after candidaemia; may need lon-
ger durations for deep-seated infections.
Consider local epidemiology.
fluconazole marginal/I;14
strong/high15
Option if not critically ill and no prior azole. At
higher doses for susceptible C. glabrata or
C. parapsilosis.
L-AmB moderate/I;14
strong/low15
Similar efficacy but higher toxicity. Consider in
cases of intolerance, limited availability, or
resistance to other agents.
voriconazole moderate/I;14
strong/
moderate15
Little advantage over fluconazole, except addi-
tional mould coverage. Note DDIs, renal
impairment, and potential TDM. For suscepti-
ble C. glabrata.
catheter-related remove catheter strong/II;14
strong/low15
If catheter removal is not possible, echinocan-
din or L-AmB or ABLC.
Prophylaxis risk of IA candidiasis fluconazole moderate/I14 Following abdominal surgery with recurrent GI
perforation or anastomotic leakage.
ICU, high-risk (non-
transplant)b
fluconazole marginal/I;14
weak/
moderate15
iv echinocandin marginal/II;14
weak/low15
Empirical febrile, at risk of infectionc,
with no microbiological
evidence
same as for targeted, echinocan-
din or fluconazole preferred
marginal/II;14
strong/
moderate15
Select antifungal based on local epidemiology
and DDI risk for the individual patient.
Pre-emptive microbiological evidence
but unproven IFI
echinocandin or fluconazoled marginal–
strong/II14
Marginal SoR with positive BDG test; Strong SoR
with positive culture.
Step-down
from iv
treatment
clinically stable with sus-
ceptible isolate and
negative blood cultures
fluconazole, voriconazole (for
C. krusei)
moderate/II;14
strong/
moderate15
From 5 to 10 days after starting echinocandin
treatment (e.g. may step down earlier if
C. parapsilosis is identified).
ABLC, amphotericin B–lipid complex; DDI, drug–drug interaction; IFI, invasive fungal infection; SoR, strength of recommendation; QoE, quality of evi-
dence; TDM, therapeutic drug monitoring.
aAs defined by ESCMID and IDSA guidelines for non-neutropenic adult patients, where QoE was defined either numerically (I indicates 1 properly
designed, randomized, controlled trial and II indicates 1 well-designed clinical trial without randomization, cohort or case-controlled analytical
studies, multiple time series or dramatic results of uncontrolled experiments) or descriptively (i.e. high, moderate, low or very low as a composite esti-
mate of effect based on study design and plausible confounding/bias, such as inconsistency, imprecision, dose response, or effect size).
bAs defined by ESCMID based on study populations that included critically ill patients with expected ICU stay of3 days, ventilation for 3 days, and
other risk factors (for example, parenteral nutrition, dialysis).
cCritically ill, with risk factors or surrogate markers for invasive candidiasis, prior azole exposure and/or culture from non-sterile sites.
dAuthor recommendation, consistent with published guideline cited.
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differences when comparing different antifungal regimens. More
data are needed to confirm the association of a specific antifungal
regimen with improved outcomes.
Several studies have highlighted that prompt administration of
adequate antifungal therapy correlates with increased survival
rates.33,112 For this reason, early diagnosis followed by timely
administration of antifungal treatment currently represents a pri-
ority to target Candida spp. infections. The implementation of this
approach, along with updated recommendations on antifungal
use for the treatment of candidiasis, has been reviewed in recently
published guidelines.14,15
Fluconazole has been the drug of choice for the treatment of
candidiasis for over two decades owing to its favourable tissue
penetration, pharmacokinetics and its low cost. Fluconazole was
initially compared with amphotericin B deoxycholate (dAmB),
demonstrating no significant differences in treatment outcomes
for patients with candidaemia but lower toxicity than amphoteri-
cin B (AmB).20 Over the years, newer compounds, such as vorico-
nazole and caspofungin, showed comparable efficacy and
reduced toxicity compared with dAmB, which has currently been
replaced by new formulations of polyenes such as liposomal
amphotericin B (L-AmB).22,23 All new antifungal drugs, in particular
echinocandins, have been compared with a standard regimen for
the treatment of candidiasis in at least one randomized controlled
trial. Micafungin was shown to be as effective as both L-AmB and
caspofungin in randomized controlled trials.25,26
The ESCMID guidelines published in 2012 no longer consider flu-
conazole to be the drug of choice for invasive candidiasis, and
recommend the use of echinocandins as first-line empirical treat-
ment.14 The 2016 IDSA guidelines also prioritize echinocandins as
first-line treatment prior to species identification and susceptibility
testing (AI, strong recommendation). Supporting evidence for
these recommendations has been published in various studies and
settings, including the ICU.103,104 Favourable characteristics of
echinocandins compared with fluconazole include fungicidal activ-
ity, a broader spectrum of activity, an excellent safety profile, and
few drug–drug interactions.15,19 However, despite growing evi-
dence of the superiority of echinocandins and the emergence of
resistance to fluconazole, especially among non-albicans strains of
Candida, fluconazole is still widely used in clinical practice for the
treatment of candidiasis. As reported in the 2016 IDSA guidelines,
fluconazole remains an acceptable empirical alternative for
patients who are not critically ill or at risk of fluconazole resistance,
and represents the drug of choice for step-down therapy according
to disease severity and susceptibility testing results.15 Other alter-
natives include voriconazole, which offers little advantage over flu-
conazole as initial therapy, and L-AmB, which can be used in case
of intolerance or limited availability of other antifungals or in case
of resistance.15 Fluconazole susceptibility testing is recommended
for all clinically relevant Candida spp. isolates, whereas for
echinocandins testing is suggested if the patient was previously
treated with an echinocandin for infections caused by C. glabrata
or C. parapsilosis.15 Voriconazole can be used as step-down ther-
apy in infections due to C. krusei.15
Areas of uncertainty remain even in the current guidelines,
including the overall duration of antifungal therapy and the opti-
mal treatment for deep-seated candidiasis, such as intra-
abdominal candidiasis.
The optimal duration of intravenous therapy for candidaemia
and invasive candidiasis has not been extensively studied. In most
trials, step-down therapy to azoles is permitted after 10 days of
treatment. In a recent non-comparative trial, step-down to an oral
azole was allowed after 5 days of intravenous treatment.113 Early
de-escalation, however, did not seem to impact survival.114
Candidaemia is usually treated for 14 days from the first negative
blood culture, requiring daily blood cultures to be performed until
negativity. Treatment duration is prolonged in deep-seated infec-
tions and endocarditis; thus it is recommended to rule out these
infections using CT scans, transoesophageal echocardiography
and fundoscopy.14
Owing to the fact that candidaemia is easier to recognize and
diagnose compared with deep-seated candidiasis, current guide-
lines mainly focus on the management of candidaemia, and trials
on abdominal candidiasis are lacking.14,63 Risk factors for intra-
abdominal candidiasis include recent surgery, necrotizing pan-
creatitis and anastomotic leaks.63 Empirical antifungal treatment
with echinocandins or L-AmB should be considered in the critically
ill or in patients with previous exposure to azoles and risk factors
for Candida spp. infection. Despite the lack of randomized trials,
antifungal therapy for patients with complicated intra-abdominal
infection is recommended when Candida sp. is grown from cul-
tures.63 Fluconazole can be adopted for targeted therapy of non-
critically ill patients who do not have previous exposure to azoles
and are not colonized with a strain with reduced susceptibility to
azoles.63
New antifungal agents
Over the past two decades, a range of antifungals has been devel-
oped and demonstrated therapeutic efficacy in severe fungal
infections. Various antifungal classes are currently available for the
treatment of candidiasis, including polyenes such as L-AmB, azoles
(fluconazole, isavuconazole and voriconazole) and echinocandins
(anidulafungin, caspofungin and micafungin). A few more antifun-
gals are currently under investigation for the treatment of candi-
daemia and invasive candidiasis, including new compounds
belonging to known classes or molecules with novel mechanisms
of action (Table 3).115
The echinocandins belong to a class of semisynthetic lipopepti-
des that inhibit the synthesis of the b-(1,3)-D-glucan component of
the cell wall of fungi. Echinocandins are characterized by fungicidal
activity, excellent tolerability, few drug–drug interactions and low
resistance rates compared with fluconazole.116 Echinocandins are
effective in the treatment of C. albicans and against non-albicans
infections, biofilms and also azole-resistant strains.117 Limitations
in the use of currently approved echinocandins include the
absence of an oral formulation and the need for daily
administration.
Rezafungin (previously CD101; Cidara Therapeutics, Inc.) is a
novel long-acting echinocandin118 characterized by a spectrum of
activity that is comparable to the other echinocandins but also a
distinct safety–pharmacokinetic/pharmacodynamic (PK/PD) pro-
file that enables high plasma drug exposure and extended interval
dosing.119–121 Rezafungin acetate is currently in development for
once-weekly intravenous administration and has also been
studied as a subcutaneous formulation.122 In vitro, rezafungin has
demonstrated potent activity against a broad range of Candida
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spp., including echinocandin- and azole-resistant strains.123
In caspofungin-resistant isolates containing FKS mutations,
which correlate with clinical failure or poor response to therapy,124
rezafungin demonstrated similar efficacy compared with micafun-
gin and high plasma drug exposure that suggested possible
advantage in preventing the emergence of resistant strains.120
Rezafungin efficacy in burden reduction was comparable to that of
micafungin in a neutropenic murine model of disseminated candi-
diasis. In that study, the rezafungin elimination half-life ranged
from 29.8 to 52.0 h.121 In healthy subjects, a dose–escalation
study125 including single or multiple doses administered weekly
(from 50 to 400 mg for up to 3 weeks) demonstrated that rezafun-
gin was safe and well tolerated, with only mild adverse events.
Half-lives were up to 130 h (400 mg dose) with reduced accumula-
tion (30%–55%) and minimal renal elimination.125 Preclinical stud-
ies determined that the rate of rezafungin protein binding is similar
to that of anidulafungin (98% in human plasma).121,126 The long
elimination half-life, coupled with the prolonged efficacy of reza-
fungin121 and its concentration-dependent killing as an echino-
candin, fit the PK/PD profile of drugs that are most effective in
larger doses, administered infrequently.106,120,127 A multicentre,
randomized, double-blind Phase 2 trial is currently ongoing to eval-
uate the efficacy and safety of rezafungin once weekly compared
with caspofungin in patients with candidaemia and invasive
candidiasis.128
SCY-078, a derivative of enfumafungin, is a semisynthetic, tri-
terpenoid, antifungal glucan synthase inhibitor, currently in devel-
opment for the treatment of invasive and mucocutaneous fungal
diseases.129 SCY-078 represents the first compound of the triterpene
class of antifungals and is currently in Phase 3 clinical development
for the treatment of invasive fungal diseases. SCY-078 has shown
good bioavailability and has been studied as oral and intravenous
formulations with once daily administration.129 High in vivo
activity against C. albicans and non-albicans strains has been shown
in animal models.129 Pre-clinical pharmacokinetic studies demon-
strated a high volume of distribution at steady state (4.7–5.3 L/kg),
suggesting extensive tissue distribution.130 An open-label study to
evaluate the efficacy and safety of SCY-078 in patients with refrac-
tory fungal diseases is currently ongoing.131
Among antifungal drugs with novel targets of action, the
new arylamidine T-2307 has shown promising activity against
C. albicans and C. glabrata both in vitro and in vivo and is currently
in Phase 1 of development.132,133 For 17 strains of echinocandin-
resistant C. glabrata, T-2307 showed a mean MIC value of
0.0083 mg/L and maintained in vivo efficacy in mice infected with
resistant strains, showing reductions in fungal burden greater
than those with caspofungin.133 Although the compound is still in
early-phase development, these findings appear promising and
support the potential use of T-2307 against echinocandin-
resistant Candida spp.
In summary, although various antifungal classes are currently in
use, several aspects such as toxicity, type of formulation and drug–
drug interactions limit their employment in daily clinical practice.
Furthermore, drug-resistant fungi are now emerging. Therefore,
new antifungals for the treatment of severe Candida infection,
including resistant strains, are awaited with widespread interest.
Conclusions
During the past 10 years, the treatment of invasive candidiasis has
been influenced by changes in the epidemiological landscape, drug
development and the pursuit of more timely intervention, by way
of both earlier diagnosis and earlier initiation of therapy. The mor-
bidity and mortality associated with invasive candidiasis remain dif-
ficult to estimate yet are largely unchanged, underscoring the need
for continued efforts in the improved use of existing modalities and
the development of new, safe and efficacious options.
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